Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies.
Antivir Ther
; 13 Suppl 2: 59-68, 2008.
Article
em En
| MEDLINE
| ID: mdl-18575192
ABSTRACT
Programmes that monitor local, national and regional levels of transmitted HIV-1 drug resistance inform treatment guidelines and provide feedback on the success of HIV-1 treatment and prevention programmes. The World Health Organization (WHO) has established a global programme for genotypic surveillance of HIV-1 drug resistance and has recommended the adoption of a consensus definition of genotypic drug resistance. Such a definition is necessary to accurately compare transmitted drug resistance rates across geographical regions and time periods. HIV-1 diversity and the large number of mutations associated with antiretroviral drug resistance complicate the development of a consensus definition for genotypic drug resistance. This paper reviews the data that must be considered to determine which of the many HIV-1 drug resistance mutations are likely to be both sensitive and specific indicators of transmitted drug resistance. The process used to create a previously published list of drug resistance mutations for HIV-1 surveillance is reviewed and alternative approaches to this process are discussed.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Organização Mundial da Saúde
/
Infecções por HIV
/
Saúde Global
/
Projetos de Pesquisa Epidemiológica
/
HIV-1
/
Farmacorresistência Viral
/
Antirretrovirais
/
Mutação
Tipo de estudo:
Guideline
/
Screening_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2008
Tipo de documento:
Article